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Genomic instability pathways in colorectal cancer (CRC) have been extensively studied, but
the role of retrotransposition in colorectal carcinogenesis remains poorly understood.
Although retrotransposons are usually repressed, they become active in several human
cancers, in particular those of the gastrointestinal tract. Here we characterize retro-
transposon insertions in 202 colorectal tumor whole genomes and investigate their asso-
ciations with molecular and clinical characteristics. We ﬁnd highly variable retrotransposon
activity among tumors and identify recurrent insertions in 15 known cancer genes. In
approximately 1% of the cases we identify insertions in APC, likely to be tumor-initiating
events. Insertions are positively associated with the CpG island methylator phenotype and
the genomic fraction of allelic imbalance. Clinically, high number of insertions is indepen-
dently associated with poor disease-speciﬁc survival.
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Retrotransposons are transposable genetic sequences thatcopy themselves into an RNA intermediate and insertelsewhere in the genome. Almost half of the human gen-
ome consists of transposon derived sequences1, however only a
few elements remain retrotransposition competent and account
for most retrotranspositions2,3. Two types of retrotransposons
have been identiﬁed in the human genome; autonomous and
non-autonomous. Autonomous elements, such as Long Inter-
spersed Nuclear Element-1s (LINE-1s) and Endogenous retro-
viruses (ERVs), provide the required machinery for
retrotransposition. On the contrary, non-autonomous elements,
such as Alus and SINE-VNTR-Alu (SVAs), require the LINE-1
machinery to retrotranspose4–7. In cancer, ~24% of somatic ret-
rotranspositions involve 3′ transduction, a process characterized
by mobilization of 3′ ﬂanking sequence which can serve as a
unique sequence revealing the insertion origin8–11.
LINE-1s are frequently repressed by promoter methylation12
and genome-wide hypomethylation is reported to lead to their
activation during tumorigenesis13,14, thus leading to high retro-
transposon activity and genome instability14–16. High retro-
transposon activity has been reported in several human cancers,
especially in tumors arising from the gastrointestinal tract, such
as colorectal cancer (CRC)10,11,17–20. Somatic insertion density in
tumors is higher in closed chromatin and late replicating regions.
Among insertions in genes, insertion density is higher in genes
with low expression10,21. Furthermore, ongoing retrotransposon
activity has been reported in CRC22. Insertion count is associated
with patient age18 and LINE-1 hypomethylation is associated
with poor survival in CRC23. LINE-1 insertions in APC have been
reported in two CRCs, indicating that these insertions may be
early tumorigenic events24,25. CRC can develop through two
distinct pathways; chromosomal instability (CIN) or micro-
satellite instability (MSI). Most sporadic CRCs follow the CIN
pathway, characterized by a large number of chromosomal
alterations. Fifteen percent of CRC cases follow the MSI pathway,
characterized by a high number of base substitutions and short
insertions and deletions26. Seventy-ﬁve percent of MSI-positive
sporadic CRCs are attributed to the CpG island methylator
phenotype (CIMP)27 which is characterized by gene promoter
hypermethylation. Although genomic instability pathways have
been studied extensively in CRC, the tumorigenic role of retro-
transposition is not fully understood. Retrotransposon insertions
have been difﬁcult to detect with previous methodological
approaches and very few genome-wide studies have been repor-
ted. Here, we characterize somatic retrotransposon insertions in
201 CRCs and one colorectal adenoma utilizing whole genome
sequencing (WGS), and investigate the associations between
somatic retrotransposon activity and clinical characteristics.
Results
Genome-wide detection of somatic retrotransposition in CRC.
To characterize the landscape of somatic retrotransposon inser-
tions in CRC we applied TraFiC10 and DELLY28 to WGS data
from 202 colorectal tumors and matched normal samples. TraFiC
was used to detect insertions without 3′ ﬂanking sequence and
DELLY was used to detect LINE-1 transductions that were not
identiﬁable by TraFiC. From the 202 tumors, 12 were MSI and
190 were microsatellite stable (MSS) including three ultra-
mutated tumors, harboring somatic POLE mutations. After
strict somatic ﬁltering, we identiﬁed a total of 5072 insertions
(Supplementary Data 1). We detected 4726 insertions with Tra-
FiC, and 346 transduction calls with DELLY. Based on visual
inspection of the paired-end read data on 100 random insertion
calls, 76 calls were evaluated as true somatic insertions, giving a
false positive rate of 24% (95% conﬁdence interval [CI], 16–34%)
(Supplementary Data 1). Additionally, 14 out of 15 3′ transduc-
tions from two samples were validated by long-distance inverse-
PCR (LDI-PCR) and Nanopore sequencing in a separate study22.
The mean number of insertions per tumor was 25 (median, 17;
interquartile range, 10–31) with high variability among tumors
(Fig. 1a). Mean number of insertions in MSS, MSI and the POLE
ultra-mutated tumors was 25, 34, and 24 respectively. The
majority of insertions (99%, 5024/5072) were LINE-1 retro-
transpositions, however we also detected 20 SVA, 13 Alu and 15
ERV insertions (Supplementary Data 1). In concordance with
previous studies10,21, insertion density was higher in closed
chromatin (1.78 insertions per Mbp) than in open chromatin
(0.96 insertions per Mbp) and in late replicating regions (repli-
cation time > 0.8, 3.06 insertions per Mbp) than in early
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Fig. 1 Distribution of somatic insertions across 202 colorectal tumors and over replication time. a Frequency of somatic insertion counts in 202 colorectal
tumors. b Insertion density over replication time. The genome was stratiﬁed by replication time in ﬁve categories where 0 referred to the earliest replication
timing. Each point represents insertion density in the corresponding category for each of the 202 tumors. Boxplot shows median, interquartile range (IQR),
and whiskers extend to the most extreme data points which are no more than 1.5 times the IQR
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replicating regions (replication time < 0.2, 0.73 insertions per
Mbp) (Fig. 1b).
Retrotranspositions are predicted to initiate ~1% of CRCs. To
characterize retrotransposon insertions in genes, all protein-
coding transcripts and the insertion polyA/T in conjunction with
gene orientation were used to assess insertion orientation (sense/
antisense). Of the 5072 insertions, 1680 (33%) were detected
within protein-coding genes, with 98% in introns (Supplementary
Data 1, Supplementary Fig. 1). We identiﬁed 353 insertions in
antisense orientation and 349 in sense orientation (Supplemen-
tary Data 1). Insertion count was higher in genes with lower
expression (median transcript per million reads [TPM] from 34
tumors) in concordance with a previous study21 (Fig. 2).
Recurrent insertions (at least two insertions) were identiﬁed in
333 protein-coding genes (Supplementary Data 2) and no
signiﬁcant enrichment of biological processes was observed after
correcting for gene length. Fifteen genes in the Cancer Gene
Census (CGC)29 displayed recurrent insertions and no clear bias
towards tumor suppressor genes or oncogenes was apparent
(Table 1).
The most frequently affected protein-coding genes were LRP1B
with 19 insertions, DLG2 with 10 insertions and PTPRD and
LSAMP both with 9 insertions. All the insertions were located in
the introns and no insertion clusters were observed (Supplemen-
tary Data 1). Higher number of insertions in antisense orientation
was observed in LRP1B where insertion orientation was available
for more insertions (Supplementary Data 1). Both LRP1B and
DLG2 have been reported to be fragile sites30 and recurrent
hotspots for HPV integration31 (Fig. 3). However, no clusters of
insertions and HPV integrations nor allelic imbalances (AI) were
apparent (Fig. 3).
Genes with highest density of recurrent insertions were RCN1
with three insertions, and COL25A1, ARAP2, and ZNF251 with
two insertions. Gene Ontology (GO) annotations associated to
these genes include protein binding for RCN1; heparin binding
and amyloid-beta binding for COL25A1; GTPase activator
activity, small GTPase binding and phosphatidylinositol-3,4,5-
trisphosphate binding for ARAP2; and RNA polymerase II
transcription activity and DNA binding transcription factor
activity for ZNF25132. None of these genes have been classiﬁed as
cancer genes29, fragile sites30 or hotspots of HPV integration31.
We also investigated whether insertions had an overall effect on
the expression of the closest genes but no signiﬁcant effect was
detected (Supplementary Fig. 2, Methods section Association test
between insertions and RNA expression).
Seventy-two insertions were identiﬁed in exons of protein-
coding genes (Supplementary Data 1, Supplementary Fig. 1). We
identiﬁed one insertion in the last exon/3 ÚTR of PIK3CA
(Supplementary Data 1) and two insertions in exon 16 of APC
(Fig. 4, Supplementary Data 1). Loss of heterozygosity and copy
number loss encompassing APC were found in both tumors, and
no other sequence variations were identiﬁed. Moreover, both
insertions were in close proximity (2,151 bp) to two previously
reported insertions24,25. The location of the insertions was
consistent with the distribution of non-synonymous point
mutations detected in APC and were predicted to disrupt the
protein reading frame of APC as previously reported24,25 (Fig. 4).
Taken together these ﬁndings, as well as the previous extensive
knowledge of the tumor-initiating role of APC in most CRCs33,34,
suggest that retrotransposon insertions may have contributed to
the early steps of tumorigenesis in 2 of the 202 colorectal tumor
patients.
Recurrent insertions in lowly expressed fragile sites. We
observed recurrent insertions in 12 out of 21 genes with high
probability of being fragile as estimated in another study30
(Supplementary Data 3). Since common fragile sites are prone to
copy number alterations (CNAs)35, we evaluated whether retro-
transposition and CNAs—in this study detected as AI36—were
correlated (Supplementary Data 3). Fragile sites with high fre-
quency of insertions seemed to display lower frequency of AI
(Fig. 5a). Next, we investigated whether high frequency of
insertions (insertion fraction/AI fraction > 1) and high frequency
of AIs (0 < insertion fraction/AI fraction < 1) could result from
differences in gene expression within fragile sites. Indeed, inser-
tion frequency seemed to be higher in genes with lower
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Fig. 2 Retrotransposon insertions in protein-coding genes. Gene expression
(median TPM values from 34 tumors) over gene insertion count groups.
Boxplot shows median, interquartile range (IQR), and whiskers extend to
the most extreme data points which are no more than 1.5 times the IQR
Table 1 Genes from the Cancer Gene Census with two or
more insertions
Gene ID Gene name Number of
insertions
(n= 202)
Cancer
census role
ENSG00000168702 LRP1B 19 TSG
ENSG00000178568 ERBB4 7 Oncogene, TSG
ENSG00000171094 ALK 5 Oncogene, fusion
ENSG00000196090 PTPRT 3 TSG
ENSG00000046889 PREX2 3 Oncogene
ENSG00000185811 IKZF1 3 TSG, fusion
ENSG00000183454 GRIN2A 2 TSG
ENSG00000144218 AFF3 2 Oncogene, fusion
ENSG00000157168 NRG1 2 TSG, fusion
ENSG00000079102 RUNX1T1 2 Oncogene,
TSG, fusion
ENSG00000151702 FLI1 2 Oncogene, fusion
ENSG00000134982 APC 2 TSG
ENSG00000189283 FHIT 2 TSG, fusion
ENSG00000085276 MECOM 2 Oncogene, fusion
ENSG00000196159 FAT4 2 TSG
Gene names are shown in italics. Cancer census role, role in cancer as deﬁned by the Cancer
Gene Census 30
TSG tumor suppressor gene
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Fig. 5 Insertion and AI frequency in 21 fragile sites. a Insertion fraction over the fraction of allelic imbalance in 21 fragile sites. b Gene expression (median
TPM values from 34 tumors) in fragile sites with high insertion fraction and fragile sites with high allelic imbalance fraction (Supplementary Data 3).
Boxplot shows median, interquartile range (IQR), and whiskers extend to the most extreme data points which are no more than 1.5 times the IQR
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expression (Exact Two-Sample Fisher-Pitman Permutation Test
for log-transformed gene expression, p= 0.04) (Fig. 5b). These
results are concordant with our data and those of another study21;
insertion density is overall negatively correlated with gene
expression.
Few active reference LINE-1s account for most transductions.
We utilized the 3′unique sequence from the transduced regions to
identify the reference source elements of LINE-1 transductions.
We detected a total of 346 transductions arising from 56 of 315
human speciﬁc full-length reference LINE-1s. Fourteen out of the
56 reference elements were previously reported to be active in
humans2,3 and 28 were reported to be active in cancer (Supple-
mentary Data 4)21. Recurrent transductions were detected from
24 LINE-1s, and in concordance with our previous study11 the
most active was the LINE-1 located in 22q12.1, which alone
accounted for 160 transductions (46%). Seven and six percent of
the transductions arose from the LINE-1s located in 9q32 and
Xp22.2, respectively. Moreover, the insertion frequencies are in
concordance with the frequencies reported by another study
across 31 different tumor subtypes (Supplementary Data 4)21.
Insertion count associates with CIMP and AI. We investigated
the associations between insertion count and molecular and
clinical characteristics. We utilized 196 colorectal tumors with
complete information on molecular and clinical variables that
were included in the model (Table 2, Supplementary Data 5). We
applied a multiple linear regression model for log-transformed
insertion counts, and hypothesized that the number of somatic
insertions may be associated with tumor location, TP53 mutation,
MSI, genomic fraction of AI36 and CIMP. The model was
adjusted for mean sequencing coverage, tumor stage, sex and age
at diagnosis (Table 2). Goodness-of-ﬁt was tested by Pearson’s
chi-square test (p= 0.99). We found that insertion count was
positively associated with CIMP (Multiple linear regression
model, p= 0.00032) and the genomic fraction of AI (Multiple
linear regression model, p= 0.0036) (Table 2). Moreover, both
associations remained signiﬁcant after including BRAF mutation
(V600E) (Multiple linear regression model, CIMP, p= 0.004; and
genomic fraction of AI, p= 0.004) and when only including MSS
samples (Multiple linear regression model, CIMP, p= 0.001; and
the genomic fraction of AI, p= 0.006). We also investigated
whether insertion breakpoints were located at sites of chromo-
somal AI (±5000 bp from each AI breakpoint, n= 40,718) how-
ever, only one colocalizing event was identiﬁed in one sample
(c827, id4279).
Insertion count associates with poor CRC survival. We applied
the Cox proportional hazards model in 192 patients with com-
plete information on molecular and clinical variables that were
used in the model (Table 3, Supplementary Data 5). Patients were
followed for 1,370 person-years (Supplementary Data 5). We
hypothesized that insertion count may be associated with disease-
speciﬁc survival (Fig. 6). The model was adjusted for tumor stage,
sex, MSI, the genomic fraction of AI, BRAF mutation and CIMP
status (Table 3). As expected, advanced tumor stage (Dukes C
and D) was strongly associated with CRC-speciﬁc survival.
However, even after adjusting for the above-mentioned covari-
ables, insertion count was independently associated with poor
disease-speciﬁc survival (Cox proportional hazards model, p=
0.0029) (Fig. 6, Table 3).
Discussion
Although retrotransposon activity is a hallmark of tumors of the
gastrointestinal tract10,11,17–20, the role of retrotransposon
insertions in CRC remains unclear with very few studies reported.
Here, we characterized the somatic landscape of retrotransposon
insertions in the largest dataset of colorectal tumor whole-
genomes reported to date, and identiﬁed signiﬁcant associations
with clinical characteristics.
Table 2 Multiple linear regression model for log insertion
counts
Coefﬁcient Std. err. z p Signif.
Intercept 0.408 0.647 0.630 5.29e-01
CIMP-H 0.607 0.169 3.60 3.22e-04 ***
Allelic Imbalance
(/10% of
reference)
0.0826 0.0284 2.91 3.64e-03 **
TP53 mutation −0.0684 0.134 −0.509 6.10e-01
MSI 0.150 0.285 0.527 5.98e-01
Mean coverage
(/10 reads)
0.309 0.0862 3.59 3.33e-04 ***
Age at diagnosis
(/10 years)
0.0331 0.0603 0.549 5.83e-01
Male 0.0570 0.123 0.464 6.42e-01
Dukes B −0.0578 0.168 −0.344 7.31e-01
Dukes C −0.0483 0.186 −0.259 7.96e-01
Dukes D 0.00490 0.211 0.0232 9.81e-01
Proximal location 0.206 0.144 1.43 1.52e-01
MSI microsatellite instability, CIMP-H CpG methylator phenotype high
Signiﬁcance codes: *** ≤ 0.001 < ** ≤ 0.01 < * ≤ 0.05 < . ≤ 0.1
Table 3 Cox proportional hazards model for disease-speciﬁc survival
Coefﬁcient Std. err. z p HR [95% CI] Signif.
Insertion count (/10) 0.108 0.0362 2.98 2.93e-03 1.11 [1.04, 1.20] **
MSI −0.258 0.642 −0.402 6.88e-01 0.773 [0.219, 2.72]
CIMP-H 0.174 0.341 0.510 6.10e-01 1.19 [0.610, 2.32]
BRAF mutation 0.790 0.447 1.77 7.68e-02 2.20 [0.918, 5.29] .
Age [55, 75) years −0.147 0.408 −0.360 7.19e-01 0.863 [0.388, 1.92]
Age≥ 75 years 0.188 0.427 0.439 6.60e-01 1.21 [0.523, 2.78]
Male 0.311 0.232 1.34 1.80e-01 1.37 [0.866, 2.15]
Dukes B 0.452 0.449 1.01 3.13e-01 1.57 [0.652, 3.79]
Dukes C 1.77 0.431 4.12 3.82e-05 5.89 [2.53, 13.7] ***
Dukes D 2.78 0.454 6.12 9.07e-10 16.2 [6.64, 39.4] ***
Allelic Imbalance (/10% of reference) −0.0583 0.0539 −1.08 2.80e-01 0.943 [0.849, 1.05]
The model was stratiﬁed by tumor location
HR Hazard ratio, CI conﬁdence interval, MSI microsatellite instability, CIMP-H CpG island methylator phenotype high
Signiﬁcance codes: *** ≤ 0.001 < ** ≤ 0.01 < * ≤ 0.05 < . ≤ 0.1
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We observed high retrotransposon activity with wide varia-
bility among tumors. We conﬁrmed higher insertion density in
late replicating regions, closed chromatin. Among insertions in
genes, we also observed higher insertion count in genes with
lower expression. The list of the most active reference LINE-1s
became also validated in this extended set of CRCs10,11,21.
A number of additional observations were made. We identiﬁed
recurrent insertions in 333 protein-coding genes, 15 of which are
included in the CGC29. The most recurrent hit was LRP1B with
19 intronic insertions. The high frequency of insertions in this
gene could be a result of various characteristics such as chromatin
state, replication timing as well as gene length and/or expression.
However, other causes such as sequence composition or somatic
selection cannot be excluded. We also observed a high frequency
of insertions at fragile sites with lower gene expression and lower
AI fraction. These ﬁndings suggest that while AI is a recurrent
feature of some fragile sites, sites with lower gene expression are
more prone to retrotransposon insertions in CRC. Yet, the
molecular basis of frequent retrotransposition in fragile sites, in
particular LRP1B, and whether these insertions are important for
the tumorigenic process remain as open questions.
Among the exonic insertions, we identiﬁed one in PIK3CA and
two in APC. PIK3CA is a known oncogene involved in colorectal
tumor progression and mutations in APC lead to colorectal tumor
initiation33,34. The insertion locations in APC were similar to two
previously reported insertions24,25 and consistent with the dis-
tribution of pathogenic somatic changes in this gene. Similar to
most pathogenic APC mutations, the insertions were predicted to
disrupt the open reading frame of the gene. These observations,
together with the previous extensive work showing the key role of
APC loss early in colorectal neoplasia33,34, suggest that retro-
transposon insertions in APC is one mechanism of CRC initiation
as previously proposed24,25, although the inactivation of APC by
retrotransposition should be functionally assessed in future stu-
dies. In addition, we identiﬁed recurrent intronic retro-
transpositions in other genes frequently mutated in CRC, such as
FAT4, and whether these insertions are important for the
tumorigenic process remains to be investigated.
The availability of patient data allowed us to investigate pos-
sible associations between somatic insertion count and various
molecular and clinical characteristics. We applied a multiple
linear regression model and found that retrotransposon activity
was positively associated with the genomic fraction of AI, and
paradoxically with CIMP even though LINE-1s are frequently
repressed by promoter methylation12. Moreover, LINE-1
methylation was associated with MSI and the CIMP in a pre-
vious study in CRC37. Of note, both CIMP and the genomic
fraction of AI are characteristic of the two distinct genetic
instability pathways in CRC. No associations with age at diag-
nosis, TP53 mutations or tumor stage were detected in contrast to
other studies18,38. These studies had signiﬁcantly smaller sample
sizes and fewer covariables were taken into account, which may
explain the discrepancy. Importantly, survival analysis revealed a
signiﬁcant association between insertion count and poor disease-
speciﬁc survival independently of other prognostic factors. Our
ﬁndings indicate that tumors with high retrotransposon activity
present characteristics of both MSS and MSI tumors, and are
associated with poor CRC-speciﬁc survival. Although, further
studies need to conﬁrm the prognostic value of retrotransposon
insertions not only in CRC, but also in other cancer types.
By characterizing the landscape of retrotransposon insertions
in a large dataset of CRCs, we found that retrotranspositions
appear to have the ability to serve as tumor-initiating events in
CRC. The association of retrotransposition events with clinical
characteristics—in particular poor prognosis—suggest that ret-
rotransposition may play a more important role in CRC than
previously thought. Further work should elucidate the timing and
mechanisms leading to high somatic retrotransposition activity in
some individuals, while others are spared. Understanding these
could provide tools for management of CRC, including
prevention.
Methods
Study subjects. The samples and the clinical data utilized in this study were
obtained from a population based series of 1042 CRCs39,40 and from a subse-
quently collected series of additional Finnish CRCs. The tumors were fresh frozen
and the corresponding normal tissues were obtained from either blood or from the
normal colon tissue. Originally 202 CRCs entered the analyses. However, one
tumor was later classiﬁed as an advanced adenomatous lesion (c232.1T). All
samples were collected after informed consent. In the great majority of cases the
consent was signed, in few cases collected before 1999 a verbal consent was derived
(signed informed consent was not required in the Finnish legislation prior to that).
For these early samples subsequent authorization for research use was derived from
the National Supervisory Authority for Welfare and Health (Dnro 421/04/044/06,
Dnro 8048/06.01.03.01/2014, Dnro 358/32/300/05, Dnro 1476/06.01.03.01/2012).
The study has been reviewed by the Ethics Committee of the Hospital district of
Helsinki and Uusima (Dnro 133/E8/03, 408/13/03/03/2009). Permission to use
patient information was obtained from the National Institute for Health and
Welfare (Dnro 53/07/2000, Dnro THL/1071/5.05.00/2011, Dnro THL/151/5.05.00/
2017).
Whole genome sequencing. WGS was performed on Illumina HiSeq 2000 with
100 bp paired-end reads. Each normal and tumor DNA was sequenced to at least
40× median coverage. Data was processed similar to GATK best practices36,41.
Transposon detection. The identiﬁcation of somatic retrotransposon insertions
was conducted utilizing the Transposon Finder in Cancer (TraFiC)10. TraFiC
default parameters were applied except for; a= 1 (RepeatMasker accuracy), s= 3
(minimum of three reads in tumor cluster), and gm= 3 (minimum of three reads
in normal cluster). In addition, paired-end reads with both ends having equal
mapping quality and above 0 were included. In these cases, the ﬁrst end of the pair
was selected as the anchor read (end mapping to non-repetitive sequence).
RepeatMasker (version open-4.0.5) and NCBI/RMBLAST 2.2.27+ were used for
retrotransposon alignment as part of TraFiC. The RepeatMasker Database release
utilized in this study was 2014012142,43. Somatic ﬁltering was performed against
germline calls from 234 normal samples (202 corresponding CRC normals, 20
myometrium samples44, and 12 blood samples45) with a 200 bp window as
described in TraFiC10. Furthermore, calls in decoy sequences from 1000 Genomes
Project Phase 2 (hs37d5)46 were ﬁltered away.
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Fig. 6 Kaplan–Meier curves by insertion count. Tumors with less than
20 somatic insertions (blue line) and tumors with 20 or more insertions
(red line)
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Detection of LINE-1 transductions. We identiﬁed 3′ and orphan transductions
utilizing DELLY structural variant (SV) calls (v 0.0.9)28,41. Filtering criteria utilized
in this study were: SV calls supported by at least three supporting discordant reads
and mapping quality > 37. SV calls were merged if they were the same DELLY type
and were within 200 bp. Merged SVs (SV length > 1000 bp) in tumors were ﬁltered
against merged SVs in the normal samples. Subsequently, we extracted the SVs
with one end of the pair within 1000 bp from the 3′ end of a reference human-
speciﬁc LINE-1 (Reference L1HS, full-length) from The European database of L1-
HS retrotransposon insertions in humans (euL1db)47, database version v1.0, date
05-10-14. The other end of the pair was used in the somatic ﬁltering, where a 200
bp window and transduction calls from the pool of normal samples above men-
tioned were applied. One transduction detected in a female coming from an LINE-
1 in Yp11.2 was ﬁltered away. Furthermore, transduction calls within 200 bp, from
the same retrotransposon family, and in the same sample were regarded as the
same insertion and merged together. The same rationale was applied for calls
detected by both DELLY and TraFiC.
Methylation. A Methylation-Speciﬁc Multiplex Ligation-dependent Probe
Ampliﬁcation assay (MS-MLPA) (Nygren AO, 2005) with the SALSA MLPA
ME042 CIMP probemix (MRC-Holland, Amsterdam, The Netherlands) was used
to determine the CIMP in an extended set of 255 tumor samples and the corre-
sponding normal colon tissue of 175 samples as a separate study. Data from normal
samples were used to determine the threshold for hypermethylation in the tumor
samples. MS-MLPA was performed according to manufacturer’s instructions48
(http://www.mrc-holland.com Accessed December 2015). In short, the assay tar-
gets the promoter region of eight tumor suppressor genes; CACNA1G, CDKN2A,
CRABP1, IGF2, MLH1, NEUROG1, RUNX3, SOCS1. The methylation level for each
probe was called using the Coffalyser software (MRC-Holland, Amsterdam, The
Netherlands). If ≥25% of the probes for one gene were methylated, the gene was
scored as methylated. If 5–8 genes, were scored as methylated, the tumor was
classiﬁed as CIMP-high (CIMP-H), and if 0–4 genes were scored as methylated it
was classiﬁed as CIMP-low (CIMP-L) tumor (Source data are provided as a Source
Data ﬁle).
RNA sequencing. Total RNA from consecutive cryosections was extracted using
RNeasy Mini Kit (Qiagen) from 34 tumors that displayed more than 50% of cancer
cell percentage (HE staining of cryosections) and RNA integrity > 6 (Agilent RNA
6000, Agilent 2100 Bioanalyzer). Paired-end RNA sequencing was performed on
the Illumina Hiseq 200049. RNA-seq data was processed using Kallisto (version
0.43.0) software50. Kallisto quantiﬁcation was executed in paired-end mode and
aligned against the Ensembl Human reference transcriptome (GRCh37_79).
Quantiﬁcation results from Kallisto were normalized and aggregated to gene-level
utilizing sleuth (version 0.28.1) R package with default ﬁltering settings51.
Visual inspection of paired-end read data. We selected 100 random insertions to
ascertain the rate of true somatic calls based on visual inspection of the paired-end
read data. Visualization was performed with BasePlayer52. Somatic calls were
visually validated as true if the insertion call was supported by discordant reads
(three+ three for TraFiC calls) and at least two split reads supporting the insertion
breakpoint and/or the polyA/T. Furthermore, the corresponding normal tissue was
also visualized to conﬁrm the somatic origin of the insertion calls.
Insertion annotation. Annotation of the insertion calls was applied by using the
inner genomic coordinates of the reciprocal clusters provided by TraFiC (P_R_POS
& N_L_POS) (Supplementary Data 1). Insertion breakpoints hitting an intron or an
exon of any protein-coding transcript (GRCh37_87) were annotated as intron/exon
hit. Insertion orientation was determined by the presence of a polyA or a polyT
(within a 200 bp window from mid point between positive breakpoint and negative
breakpoint) in conjunction with gene orientation. PolyA was called when at least
two forward strand reads started with three or more consecutive “A” bases. We used
sequences of other reads to detect “A” repeats in the reference (i.e., the polyA call
was discarded if “A” repeat was found in the middle of other overlapping read).
PolyT was called using the reverse strand reads with three or more consecutive “T”
bases at the end of the read sequence not present in the reference as described above
(Supplementary Data 1). Insertion strand with respect to reference was deﬁned as
reverse when a polyA was called, and deﬁned as forward when a polyT was called.
Sense insertions were deﬁned when the insertion strand with respect to reference
was reverse in genes in plus orientation or forward in genes in minus orientation.
Antisense insertions were deﬁned when insertion strand with respect to reference
was reverse in genes in minus orientation or forward in genes in plus orientation
(Supplementary Data 1). Replication time fractions were extracted from Chen
et al.53. Insertion density was deﬁned as number of insertions divided by the total
number of base pairs of each replication time fraction. Open chromatin was deﬁned
as DNAse regions that were overlapping in at least two out of the four cell lines
(RKO, LoVo, CaCo2, and Gp5D) (GSE83968)54 in the 1000 Genomes Project pilot
style callable regions55. Closed chromatin regions were deﬁned as the above-
mentioned callable regions minus the open chromatin regions.
GO analysis. We applied GO analyser for RNA-seq and other length biased data
(Goseq)56 with R version 3.5.1 to identify enrichment of biological processes in
genes with recurrent insertions. Genes with recurrent insertions were deﬁned as
genes with two or more insertions. We utilized Wallenius approximation and p-
values were corrected using Benjamini and Hochberg method. Enrichment was
considered for FDR corrected p-values above 0.05.
Fragile sites. The 21 fragile sites were deﬁned as genes with more than 0.85
probability of being fragile (Random forest 3 predictors)30. Genomic coordinates
were lifted to GRCh37/Hg19 with https://genome.ucsc.edu/cgi-bin/hgLiftOver57
and regions with no converted coordinates were excluded
(chr10:46597226–48877831, chr10:45970128–48447930). The fraction of AI was
calculated as the number of focal AI events per fragile site (both breakpoints of
each AI call within the fragile site coordinates) divided by the total number of AI
events in 1699 tumors36. Insertion fraction was calculated as the number of
insertions per fragile site divided by the total number of insertions detected in 202
patients. Fragile site categories were deﬁned based on the ratio of insertion fraction/
AI fraction. AI high; 0 < ratio < 1, and Retrotransposon-high; ratio > 1.
Mutation analysis in CRC genes. Somatic changes in BRAF, KRAS, TP53 and
APC were called using MuTect (version 1.1.4) with default parameters
(GRCh37_78)36,41. Subsequent ﬁltering criteria were minimum coverage of 4,
minimal allelic fraction of 10 and minimum quality score 2052. For KRAS, muta-
tions in codons 12, 13, 61, 117, and 146 in any transcript were classiﬁed as
mutation positive and for BRAF, only hotspots in V600E in any transcript were
considered as mutation positive. All non-synonymous changes in any transcript of
TP53 were classiﬁed as mutation positive. In addition, non-synonymous changes in
APC (ENST00000457016) from 234 MSS tumors36 were utilized for Fig. 4. Figure 4
was created with http://www.cbioportal.org/tools.jsp58,59 and modiﬁed with
Inkscape (http://www.inkscape.org)60.
Association test between insertions and RNA expression. For the 827 inser-
tions identiﬁed in any of the 34 tumors, we investigated the effect on the expression
of the 642 distinct closest genes. For each sample and each gene the TPM values
were extracted and ranked in ascending order. Consequently, the rank number
corresponding to the sample with the insertion was recorded for each gene. We
computed the sum-of-squared error statistic (Chi-square test) for the frequency
table to test whether the rank values of the samples with insertion were uniformly
distributed (no insertion effect on gene expression). Furthermore, 100,000 per-
mutations with randomized rank numbers were applied but no signiﬁcant effect
was observed (Supplementary Fig. 2). Tests were performed using R versions 3.4.3
or 3.3.0.
Multiple linear regression analysis. To model retrotransposon insertion counts
we applied a multiple linear regression model for log-transformed insertion counts.
Spearman correlation matrix (R package PerformanceAnalytics) and variance
inﬂation factors (vif function in R package car) were computed to evaluate possible
collinearity among explanatory variables61,62. Model ﬁt was assessed by plotting
residuals against ﬁtted values, theoretical normal quantiles and leverage (Supple-
mentary Figs. 3–5). All tests were performed using R version 3.3.263.
Cox proportional hazards regression analysis. We applied the Cox proportional
hazards regression to study the association between disease-speciﬁc survival with
retrotransposon insertion counts. The time variable was deﬁned as days since
diagnosis or operation. Patients that were alive in the last status assessment were
censored at that date (survival status was assessed periodically using the Population
Register Centre of Finland with the most recent assessment in 2016). Death from
other causes than CRC were also deﬁned as censored events. Proportional hazards
assumptions were assessed by Grambsch-Therneau test for proportional hazards
and evaluation for a non-zero slope of the scaled Schoenfeld residuals versus time
(Supplementary Fig. 6). Based on inspection of the scaled Schoenfeld residuals, the
model was stratiﬁed by tumor location. Inﬂuential observations were assessed with
dfbeta and martingale residuals (Supplementary Figs. 7 and 8). All tests were
performed using R version 3.3.263.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The raw sequencing data produced in this study is not available due to the presence of
germline data- and thus identiﬁable information-which we do not have the speciﬁc
consent to distribute. The whole-genome somatic point mutations have been deposited
in the EGA database under the accession code EGAS00001003010. Gene expression
values have been deposited in the Zenodo database under the Digital Object Identiﬁer
[https://doi.org/10.5281/zenodo.3241399]. The methylation source data and the data
underlying Fig. 3 are provided as Source Data ﬁles. All the other data supporting the
ﬁndings of this study are available within the article and its Supplementary Information
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